三阴性乳腺癌术后辅助强化治疗研究进展

Progress in adjuvant intensive therapy for triple negative breast cancer

三阴性乳腺癌整体上表现为侵袭性强、术后复发率高,在完成标准辅助治疗后进行强化治疗,有望进一步降低复发风险,提高患者生存率。CREATE-X研究率先开启了三阴性乳腺癌术后辅助强化治疗的新模式,OlympiA研究为携带BRCA基因胚系突变的三阴性乳腺癌提供了辅助强化的佐证,SYSUCC-001研究证实节拍、长疗程卡培他滨治疗可降低复发风险,另外还有多项研究探索了铂类、卡培他滨在基底样型和非基底样型三阴性乳腺癌中辅助强化治疗的疗效。该文对以上研究进行详细解读并作相关评述,以期为三阴性乳腺癌辅助强化治疗的临床决策提供参考。

Triple negative breast cancer(TNBC)is generally characterized by strong invasion and high recurrence rate after operation.Intensive treatment after standard adjuvant therapy is expected to further reduce the recurrence risk and improve the survival rate of patients.CREATE-X research took the lead in opening a new mode of adjuvant intensive treatment for TNBC after surgery.OlympiA study provided the evidence of adjuvant intensive treatment for TNBC patients with BRCA germline mutation.SYSUCC-001 study confirmed that metronomic chemotherapy with long-term capecitabine treatment could reduce the risk of recurrence.In addition,several studies have explored the efficacy of platinum and capecitabine in adjuvant intensive treatment in basal like and non-basal like TNBC.In this paper,the above studies were interpreted and reviewed in detail,in order to provide reference for the clinical decision-making of adjuvant intensive therapy for TNBC patients.